Speaking with the PharmTech Group at INTERPHEX 2025, Dave Loula, global product director, ITT Engineered Valves, discusses innovation in advanced sensing technologies that addresses customer need for reliable valve function.
The primary focus in valve technology advancements is reliability, particularly in pharmaceutical applications where system integrity and contamination prevention are critical. Talking with the PharmTech Group at INTERPHEX 2025, Dave Loula, global product director, ITT Engineered Valves, emphasizes that customers seek valves that are easy to maintain and provide consistent performance. Key innovations in advanced sensing technologies are those that address customers’ need for reliable and easily maintained valves.
“The advanced sensing—we term this ‘Integrated Sensing Platform,’ our new ISP technology—is part of that reliability solution that the customers are looking for when they're looking for feedback on their valves. They want to make sure that they're getting a reliable sensing of the position of the valve so that they know that a valve is in the open position or in the closed position so they can go on and do their particular operation. The ISP, which is a very small, compact device that fits on top of one of our valves, provides that type of reliable feedback on valve operation,” Loula says.
ISP technology plays a crucial role in maintaining process integrity, reducing the risk of system failures, and ensuring compliance with stringent regulatory requirements. Additionally, the broader platform includes sensors, actuation systems, and advanced monitoring solutions to support end users, original equipment manufacturers, and distributors, Loula explains.
Loula is most looking forward to engaging with industry stakeholders at INTERPHEX to foster collaboration and knowledge exchange. He believes that such engagement ensures that emerging needs in pharmaceutical valve technology are met with cutting-edge solutions.
Click above to view the full interview.
Attendees can visit ITT at Booth #3337 at INTERPHEX 2025, being held in New York City on April 1–3.
Click here for more conference coverage.
David Loula, Global Product Director, ITT Engineered Valves
David Loula has extensive experience in the biopharmaceuticaland industrial sectors, specializing in sales,product management, and business strategy. Currently serving as global product director and previously as global marketing manager at ITT Engineered Valves since August 2012, Loula has driven significant product initiatives and marketing strategies. Prior roles include business development manager at ITT Industries and sales manager at ITT PureFlo, where he managed sales efforts for the Pure-Flo hygienic diaphragm valve product line across a 15-state region. Loula's educational background includes a Bachelor of Science in Mechanical Engineeringdegree from the University of Michigan.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.